🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million new cases annually. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Global Access

Based on results published in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The research involved nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea around the world.